The pathophysiology of alveolar osteonecrosis of the jaw: Anticardiolipin antibodies, thrombophilia, and hypofibrinolysis

Journal of Laboratory and Clinical Medicine

Volumn 127, Issue 5, 1996, Pages 481-488

  Gruppo, Ralph ^b   Glueck, Charles J ^a   Mcmahon, Robert E ^b   Bouquot, Jerry ^b   Rabinovich, Brian A ^b   Becker, Ann ^b   Tracy, Trent ^b   Wang, Ping ^b  

^a JEWISH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOPROTEIN A; PROTEIN C; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; BONE NECROSIS; FACE PAIN; FEMALE; FIBRINOLYSIS; HUMAN; IMMUNOLOGY; JAW; JAW DISEASE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; THROMBOSIS;

ADOLESCENT; ADULT; AGED; ALVEOLAR PROCESS; ANTIBODIES, ANTICARDIOLIPIN; FACIAL PAIN; FEMALE; FIBRINOLYSIS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; JAW DISEASES; LIPOPROTEIN(A); MALE; MIDDLE AGED; OSTEONECROSIS; PROTEIN C; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030138634     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(96)90065-7     Document Type: Article

References (49)

1. Bouquot JE, Roberts AM, Person P, Christian J. Neuralgiainducing cavitational osteonecrosis (NICO). Osteomyelitis in 224 jawbone samples from patients with facial neuralgia. Oral Surg Oral Med Oral Pathol 1992;73:307-19.
2. Bouquot JE. Neuralgia-inducing cavitational osteonecrosis. In: Neville BW, Damm DD, Allen CM, Bouquot JE, eds. Oral and maxillofacial pathology. Philadelphia: Saunders, 1995:631-2.
3. Glueck CJ, McMahon RE, Buoquot J, et al. The pathophysiology of idiopathic osteonecrosis of the jaws: thrombophilia and hypofibrinolysis [Abstract]. J Invest Med 1995;43(suppl 2):234A.
4. Edelberg J, Pizzo SV. Why is lipoprotein(a) relevant to thrombosis? Am J Clin Nutr 1992;56:791S-2S.
5. Glueck CJ, Glueck HI, Tracy T, Speirs J, McCray C, Stroop D. Relationship between Lp(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. Metabolism 1993;42:236-46.
6. Bick RL, Baker WF. Anticardiolipin antibodies and thrombosis. Hematol Oncol Clin North Am 1992;6:1287-99.
7. Triplett DA. Antiphospholipid antibodies and thrombosis: a consequence, coincidence, or cause? Arch Pathol Lab Med 1993;117:78-88.
8. Bick RL, Baker WF. The antiphospholipid and thrombosis syndromes. Med Clin North Am 1994;78:667-84.
9. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine 1989;68:366-74.
10. Nagasawa K, Ishii Y, Mayumi T, et al. Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities. Ann Rheum Dis 1989;48:672-6.
11. Alijotas J, Argemi M, Barquinero J. Kienbock's disease and antiphospholipid antibodies. Clin Exp Rheumatol 1990;8: 297-8.
12. Seleznick MJ, Silveira LH, Espinoza LR. Avascular necrosis associated with anticardiolipin antibodies. J Rheumatol 1991; 18:1416-7.
13. Vela P, Batlle E, Salas E, Marco P. Primary antiphospholipid syndrome and osteonecrosis [Letter]. Clin Exp Rheumatol 1991;9:545-6.
14. Asherson RA, Liote F, Page B, et al. Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 1993;20:284-8.
15. Migliaresi S, Picillo U, Ambrosone L, Di Plama G, et al. Avascular necrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies. Lupus 1994; 3:37-41.
16. Glueck CJ, Freiberg R, Glueck HI, et al. Hypofibrinolysis: a common, major cause of osteonecrosis. Am J Hematol 1994; 45:156-66.
17. Glueck CJ, Rorick MH, Schmerler M, et al. Hypofibrinolytic and atherogenic risk factors for stroke. J LAB CLIN MED 1995;125:319-25.
18. Glueck CJ, Glueck HI, Greenfield D, et al. Protein C and S deficiency, thrombophilia, and hypofibrinolysis: pathophysiologic causes of Legg-Perthes Disease. Pediatr Res 1994;35: 383-8.
19. Glueck CJ, Crawford A, Roy D, et al. Association of antithrombotic factor deficiencies and hypofibrinolysis with Legg-Perthes disease. J Bone Joint Surg 1996;78-A:3-13.
20. Smirnov MD, Triplett DT, Comp PC, Esmon NC, Esmon CT. On the role of phosphatidyl ethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995;95:309-16.
21. Chang CC, Greenspan A, Gershwin ME. Osteonecrosis: current perspectives on pathogenesis and treatment. Semin Arthrtis Rheum 1993;23:47-69.
22. Mankin JH. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 1992;326:1473-9.
23. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika 1965;52:591-611.
24. Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames, Iowa: Iowa State University Press, 1980:1-507.
25. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that induces a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4.
26. Matsuura E, Igarashi M, Igarashi Y, et al. Molecular studies on phospholipid-binding sites and cryptic epitopes appearing on beta 2-glycoprotein I structure recognized by anticardiolipin antibodies. Lupus 1995;4:S13-7.
27. McGee GS, Pearce WH, Sharma L, et al. Antiphospholipid antibodies and arterial thrombosis. Case reports and a review of the literature. Arch Surg 1992;127:342-6.
28. Palacios-Boix A, Alarcon-Segovia D. Antibodies to endothelial cells and vascular damage. In: New clues for the study of vascular damage in autoimmune disease. Cervera R, Khamarshta MA, Hughes GRV, eds. Boca Raton: CRC Press, 1994:1-16.
29. Chancellor AM, Cull RE, Kilpatrick DC, Warlow CP. Neurological disease associated with anticardiolipin antibodies in patients without systemic lupus erythematosus: clinical and immunological features. J Neurol 1991;238:401-7.
30. Pope JM, Canny CL, Bell DA. Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant. Am J Med 1991;90:299-309.
31. Gorman DG, Cummings JL. Neurobehavioral presentations of the antiphospholipid antibody syndrome, J Neuropsychiatry Clin Neurosci 1993;5:37-42.
32. Tietjen GE. Migraine and antiphospholipid antibodies. Cephalalgia 1992;12:69-74.
33. Glueck CJ, Glueck HI, Mieczkowski L, Tracy T, Speirs J, Stroop D. Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis? Thromb Haemost 1993;69:460-5.
34. Glueck CJ, Glueck HI, Welch M, et al. Familial idiopathic osteonecrosis mediated by familial hypofibrinolysis with high levels of plasminogen activator inhibitor. Thromb Haemost 1994;71:195-8.
35. Van Veldhuizen RI, Neff J, Murphey MD, Bodensteiner D, Skikne BS. Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip. Am J Hematol 1993;44:243-8.
36. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1944;369:64-7.
37. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330: 517-22.
38. Glueck CJ, Freiberg R, Glueck HI, Tracy T, Stroop D, Hamer T. Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high Lp(a), and therapy with Stanozolol. Am J Hematol 1995;48:213-20.
39. Wannfors K. Vascular changes after experimentally induced inflammation in the mandible. Int J Oral Maxillofac Surg 1989;18:79-82.
40. Wannfors K, Hammarstrom L. A proliferative inflammation in the mandible caused by implantation of an infected dental root. A possible experimental model for chronic osteomyelitis. Int J Oral Maxillofac Surg 1989;18:179-83.
41. Wannfors K, Gazelius B. Blood flow in jawbones affected by chronic osteomyelitis. Br J Oral Maxillofac Surg 1991:29;147-53.
42. Kenzora JE, Glimcher MJ. Accumulative cell stress: the multifactorial etiology of idiopathic osteonecrosis. Ortho Clin N Am 1985:16;669-79.
43. Cruess RL. Osteonecrosis of bone. Current concepts as to etiology and pathogenesis. Clin Orthop Rel Res 1986:208; 30-9.
44. Cruess RL. Steroid-induced osteonecrosis: a review. Can J Surg 1981:24;567-71.
45. Blei F, Wilson EL, Mignatti P, Rifkin DB. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 1993:155;568-78.
46. Bouquot JE, Christian J. Long-term effects of jawbone curettage on the pain of facial neuralgia. J Oral Maxillofac Surg 1995:53;387-97.
47. Ingle JI, Bakland LK. Endodontics. 4th ed. Baltimore: Williams and Wilkins 1994:581-2.
48. Bick RL. Hypercoagulability and thrombosis. Med Clin North Am 1994;78:635-65.
49. Rivier G, Herranz MT, Khamashta MA, Huges GRV. Thrombosis and antiphospholipid syndrome: a preliminary assessment of three antithrombotic treatments. Lupus 1994: 3;85-90.